Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Protokylol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 15/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 14/20 | 0.73 |
| ▸ | ADRB3 | P13945 | 13/20 | 0.73 |
| ▸ | ADRA1D | P25100 | 11/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.73 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.73 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Protokylol SCHEMBL50567 | 0.98 | ADRB2 (0.76) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| Protokylol SCHEMBL210099 | 0.97 | ADRB2 (0.74) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL11191804 | 0.85 | ADRB2 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL11670365 | 0.85 | ADRB3 (0.70) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL7154320 | 0.83 | ADRB2 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL7154315 | 0.83 | ADRB2 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL30051139 | 0.80 | ADRB3 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL8305498 | 0.80 | ADRB3 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL8305494 | 0.80 | ADRB3 (0.68) | ADRB2ADRB1ADRB3ADRA1DADRA1A | |
| SCHEMBL10446972 | 0.80 | ADRB2 (0.64) | ADRB2ADRB1ADRB3ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | MACKAY JON (US) | 2012-02-02 | — | — | US | claimed |
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | MACKAY JON (US) | 2012-02-02 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029085-A1 | STABILIZATION OF QUINOL COMPOSITION SUCH AS CATECHOLAMINE DRUGS | ADRA2C, ADRB2, ADRB1 | ADRB2 2/4885ADRB1 3/4885ADRB3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.